Ovarian Cancer
2,068
350
470
920
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
310 trials with published results (15%)
Research Maturity
920 completed trials (44% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.7%
242 terminated out of 2068 trials
79.2%
-7.4% vs benchmark
8%
170 trials in Phase 3/4
34%
310 of 920 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 920 completed trials
Clinical Trials (2068)
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
Opportunistic Salpingectomy During Bariatric Surgery for Ovarian Cancer Prevention
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Ovarian Cancer Identification on CT Using Deep Learning
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
A Study of PHST001 in Advanced Solid Tumors
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
A Study of MGC026 in Participants With Advanced Solid Tumors
Implementation of New Models of Ovarian Carcinoma Resistant to Therapy
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations